[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858-751-4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 63, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1037500, "exercisedValue": 0, "unexercisedValue": 9922011}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 54, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 58, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tighe M. Reardon C.F.A., CPA", "age": 47, "title": "Acting Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tommy  Diraimondo Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Brenda  Van Vreeswyk", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 39, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 41.47, "open": 41.19, "dayLow": 39.01, "dayHigh": 41.19, "regularMarketPreviousClose": 41.47, "regularMarketOpen": 41.19, "regularMarketDayLow": 39.01, "regularMarketDayHigh": 41.19, "beta": 3.707, "forwardPE": -23.832336, "volume": 474453, "regularMarketVolume": 474453, "averageVolume": 865179, "averageVolume10days": 696050, "averageDailyVolume10Day": 696050, "bid": 39.73, "ask": 39.92, "bidSize": 200, "askSize": 100, "marketCap": 2063657856, "fiftyTwoWeekLow": 5.65, "fiftyTwoWeekHigh": 65.6, "priceToSalesTrailing12Months": 283.19717, "fiftyDayAverage": 48.3516, "twoHundredDayAverage": 24.4936, "currency": "USD", "enterpriseValue": 1435848832, "floatShares": 21167234, "sharesOutstanding": 51850700, "sharesShort": 2986118, "sharesShortPriorMonth": 3301160, "sharesShortPreviousMonthDate": 1714435200, "dateShortInterest": 1717113600, "sharesPercentSharesOut": 0.057600003, "heldPercentInsiders": 0.09422, "heldPercentInstitutions": 0.96203005, "shortRatio": 3.51, "shortPercentOfFloat": 0.1145, "impliedSharesOutstanding": 51850700, "bookValue": 12.65, "priceToBook": 3.146245, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -55594000, "trailingEps": -1.2, "forwardEps": -1.67, "pegRatio": -0.22, "enterpriseToRevenue": 197.043, "enterpriseToEbitda": -20.273, "52WeekChange": 2.4518647, "SandP52WeekChange": 0.24598539, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "JANX", "underlyingSymbol": "JANX", "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "firstTradeDateEpochUtc": 1623418200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3a638123-d3da-3133-96c7-e6e8cabf84b3", "messageBoardId": "finmb_676965261", "gmtOffSetMilliseconds": -14400000, "currentPrice": 39.8, "targetHighPrice": 100.0, "targetLowPrice": 47.0, "targetMeanPrice": 68.57, "targetMedianPrice": 64.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 651763008, "totalCashPerShare": 12.571, "ebitda": -70825000, "totalDebt": 24185000, "quickRatio": 61.851, "currentRatio": 62.086, "totalRevenue": 7287000, "debtToEquity": 3.688, "revenuePerShare": 0.159, "returnOnAssets": -0.08741, "returnOnEquity": -0.114980005, "freeCashflow": -33208876, "operatingCashflow": -51501000, "revenueGrowth": -0.389, "operatingMargins": -16.103039, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-27"}]